Back

Deutsche Bank upgrades AstraZeneca to Hold after mixed drug-trial results

Verifying
  • Deutsche Bank upgraded AstraZeneca's stock rating from Sell to Hold.
  • Tozorakimab delivered strong Phase III results and received FDA priority review.
  • The rating change followed mixed outcomes from AstraZeneca's drug trials.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.